A model of an empagliflozin molecule is placed in a time capsule at the groundbreaking ceremony for Boehringer Ingelheim's Chemical Innovation Plant. From L-R: Malu Dreyer, Minister President of Rhineland-Palatinate; Boehringer Ingelheim chairman Hubertus von Baumbach; and German Chancellor Olaf Scholz (Sebastian Gollnow/picture-alliance/dpa/AP Images)
May 2, 2023 03:00 PM EDT
R&D
Manufacturing

Boehringer In­gel­heim to con­struct a $300M+ fa­cil­i­ty at its HQ

Tyler Patchen

News Reporter

Boehringer In­gel­heim plans to make a ma­jor in­vest­ment in­to man­u­fac­tur­ing chem­i­cals and ac­tive phar­ma­ceu­ti­cal in­gre­di­ents close to home.

The Ger­man phar­ma on Tues­day broke ground …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times